- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
BTK Inhibitors in B-Cell Lymphomas | Supplements and Featured Publications
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
September 22, 2020
Article
Bruton tyrosine kinase (BTK) inhibitors play an important role in the therapeutic spectrum of B-cell lymphomas.
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
September 14, 2020
Video
Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
September 11, 2020
Article
Shuo Ma, MD, PhD, discusses the evolving role of BTK inhibitors in B-cell malignancies, ongoing research efforts examining their use, safety concerns to be aware of with the agents, and next steps for research.
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
September 11, 2020
Article
Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
September 10, 2020
Article
Kami J. Maddocks, MD, discusses the utility of BTK inhibitors in B-cell malignancies, challenges that are still faced in the space, and areas primed for additional development.
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
September 09, 2020
Video
Shuo Ma, MD, PhD, highlights ongoing research with BTK inhibitors in B-cell malignancies.
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
September 09, 2020
Video
Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.
Building on Current Understandings of BTK Inhibition in CLL, MCL
August 19, 2020
Article
Nilanjan Ghosh, MD, PhD, discusses the role of BTK inhibitors in B-cell malignancies and ongoing research with each agent.
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
July 20, 2020
Video
John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
July 14, 2020
Video
Steven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
July 14, 2020
Video
Kami J. Maddocks, MD, discusses the role of zanubrutinib in B-cell malignancies.
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
March 23, 2020
Article
Constantine S. Tam, MD, MBBS, highlights the impact of BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia.
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
March 20, 2020
Article
Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
March 20, 2020
Article
During an OncLive® Scientific Interchange, community and academic oncologists review the current treatment landscape and evaluate therapeutic strategies involving BTK inhibitors in B-cell lymphomas.
Dr. Tam on FDA Approved BTK Inhibitors in Hematologic Malignancies
February 12, 2020
Video
Constantine S. Tam, MD, MBBS, discusses the 3 FDA approved BTK inhibitors in hematologic malignancies: ibrutinib, acalabrutinib, and zanubrutinib.
Dr. Tam on Zanubrutinib Approval in MCL
February 12, 2020
Video
Constantine S. Tam, MD, MBBS, discusses the FDA approval of zanubrutinib in mantle cell lymphoma.
Dr. Kahl on BTK Inhibitor Time-Definite Trials in CLL
February 12, 2020
Video
Brad Kahl, MD, discusses trials looking at time-definite therapy looking at BTK inhibitor combinations in chronic lymphocytic leukemia.
Dr. Tam on Varying BTK Inhibitors in Mantle Cell Lymphoma
January 08, 2020
Video
Constantine S. Tam, MD, MBBS, discusses a comparison of BTK inhibitors in mantle cell lymphoma.
Dr. Kahl on Frontline BTK Inhibitor Selection in CLL
January 02, 2020
Video
Brad Kahl, MD, discusses choosing between BTK inhibitors ibrutinib and acalabrutinib for frontline treatment of chronic lymphocytic leukemia.